Please use this identifier to cite or link to this item:
PIRA download icon_1.1View/Download Full Text
Title: (-)-Epigallocatechin gallate derivatives for inhibiting proteasome
Authors: Chan, TH 
Lam, WH
Chow, LMC 
Dou, QP
Kuhn, DJ
Kazi, A
Wan, SB
Landis-Piwowar, KR
Issue Date: 5-Jun-2012
Source: US Patent 8,193,377 B2. Washington, DC: US Patent and Trademark Office, 2012.
Abstract: (-)-EGCG, the most abundant catechin, was found to be chemopreventive and anticancer agent. However, (-)-EGCG has at least one limitation: it gives poor bioavailability. This invention provides compounds of generally formulae below, wherein R₁₁, R₁₂, R₁₃, R₂₁, R₂₂, R₂, R₃, and R₄ are each independently selected from the group consisting of --H, and C₁ to C₁₀ acyloxyl group; and R₅ is selected from the group consisting of --H, C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₃-C₇-cycloalkyl, phenyl, benzyl and C₃-C₇-cycloalkenyl, whereas each of the last mentioned 7 groups can be substituted with any combination of one to six halogen atoms; at least one of R₁₁, R₁₂, R₁₃, R₂₁, R₂₂, R₂, R₃ and R₄ is --H, which were found to be more potent than their non-protected counterparts, which can be used as proteasome inhibitors to reduce tumor cell growth.
Rights: Assignee: The Hong Kong Polytechnic University.
Assignee: Wayne State University.
Assignee: University of South Florida.
Appears in Collections:Patent

Files in This Item:
File Description SizeFormat 
us8193377b2.pdf2.06 MBAdobe PDFView/Open
Show full item record

Page views

Last Week
Last month
Citations as of Jun 4, 2023


Citations as of Jun 4, 2023

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.